Management tracks: Browne out as Revance CEO; plus CytomX, Aligos, Angion, Savonix and Global Cancer Technology

Revance Therapeutics Inc. (NASDAQ:RVNC), which is developing neuromodulators for aesthetic and therapeutic indications, hired board member Mark Foley as president and CEO. He succeeds Dan Browne, who resigned from those roles as well as the board "due to a misjudgment in handling an employee matter," according to the company. Foley was chairman, president and CEO of Zeltiq Aesthetics Inc, which Allergan plc (NYSE:AGN) acquired.

CytomX Therapeutics Inc. (NASDAQ:CTMX) said Amy Peterson has joined the oncology company as EVP and chief development officer. She was CMO of immuno-oncology at BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160)...